What's New
6.11.09
"New Study Demonstrates NanoScan`s Novel Contrast Agent May Identify Heart Attack in Waiting" company press release
"New Study Demonstrates NanoScan`s Novel Contrast Agent May Identify Heart Attack in Waiting" company press release
Lymph nodes are frequently the site for metastases from several types of cancer. Lymph node imaging plays a critical role in staging patients and determining appropriate patient management. The two anatomical imaging modalities currently used for identifying lymph nodes are computed tomography (CT) and magnetic resonance imaging (MRI). However, CT and MRI alone cannot distinguish between nodes enlarged due to inflammation and enlarged cancerous nodes, nor can they identify cancerous nodes that are not enlarged. Therefore, the current practice is to assume that enlarged nodes (typically greater than ten millimeters in size) are cancerous and to perform biopsy or surgery to establish their true status. By accumulating in macrophage cells associated with non-cancerous lymph node tissue, N1177 may facilitate differentiation between cancerous nodes and other nodes. N1177 could enable doctors using CT imaging to have improved diagnostic confidence in differentiating between normal and cancerous lymph nodes, irrespective of node size.
NanoScan Imaging, LLC
2250 Berks Road
Lansdale, PA 19446
P: 610-647-3231
info@nanoscanimaging.com
www.nanoscanimaging.com